| Gender (n, %) | 0.172 | 0.678 |
| Male | 27 (64.3) | 47 (68.1) |
| Female | 15 (35.7) | 22 (31.9) |
| Primary disease (n, %) | 0.016 | 0.899 |
| AML | 22 (52.4) | 37 (53.6) |
| ALL | 20 (47.6) | 32 (46.4) |
| Disease status at HSCT (n, %) | 1.873 | 0.392 |
| First CR | 19 (45.2) | 39 (56.5) |
| Second and other CR | 16 (38.1) | 18 (26.1) |
| Relapse | 7 (16.7) | 12 (17.4) |
| Disease status at HSCT (n, %) | 1.332 | 0.248 |
| First CR | 19 (45.2) | 39 (56.5) |
| Other | 23 (54.8) | 30 (43.5) |
| Extramedullary infiltration (n, %) | 2.538 | 0.111 |
| Yes | 8 (19.0) | 6 (8.7) |
| No | 34 (81.0) | 63 (91.3) |
| Conditioning regimen (n, %) | 0.082 | 0.775 |
| Bu/Cy-based | 30 (71.4) | 51 (73.9) |
| TBI/Cy-based | 12 (28.6) | 18 (26.1) |
| Gender of donor-recipient (n, %) | 5.669 | 0.017 |
| Identical | 19 (45.2) | 47 (68.1) |
| Different | 23 (54.8) | 22 (31.9) |
| Donor-recipient ABO compatibility (n, %) | 0.014 | 0.907 |
| Compatible | 19 (45.2) | 32 (46.4) |
| Incompatible | 23 (54.8) | 37 (53.6) |
| Abnormal markers | NA | NA |
| t(9;22) | 8 (19.0) | 13 (18.8) |
| MLL/AF4 | 1 (2.4) | 3 (4.3) |
| FLT3/ITD | 2 (4.8) | 1 (1.4) |
| MRD | 0.014 | 0.906 |
| Yes | 12 (28.6) | 19 (27.5) |
| No | 30 (71.4) | 50 (72.5) |
| MNC (× 108/kg) | 11.74 (3.98–31.03) | 14.57 (3.57–47.11) | NA | NA |
| CD34 + cells(× 106/kg) | 5.84 (3.43–23.30) | 8.33 (3.07–35.7) | NA | NA |
| Time for implantation of neutrophils (d) | 12 (9–19) | 13 (10–26) | NA | NA |
| Time for implantation of PLT(d) | 13 (8–30) | 13 (9–26) | NA | NA |
